Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1062 | 1034 | 1078 | 1218 | 1472 | 1841 |
Fund Return | 6.17% | 3.41% | 7.83% | 6.79% | 8.04% | 6.29% |
Place in category | 1187 | 1611 | 1443 | 780 | 404 | 398 |
% in Category | 55 | 75 | 74 | 44 | 26 | 41 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pioneer US Fndmntl Growth F EUR ND | 3.02B | 9.93 | 11.21 | 14.68 | ||
Pioneer US Fndmntl Growth C EUR ND | 3.02B | 9.80 | 10.64 | 14.37 | ||
PioneerFunds Euro Eq Value C EUR ND | 2.77B | 4.54 | 6.33 | 4.52 | ||
Core Series Core Champions E EUR ND | 833.35M | 2.00 | -1.21 | 2.41 | ||
Pioneer Top Euro Players H EUR ND | 646.84M | 6.19 | 6.81 | 6.16 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 180.4M | 5.53 | 4.70 | 5.19 | ||
European Growth Fund E Acc EUR | 21.67M | 5.25 | 3.90 | 4.40 | ||
European Growth Fund Y Acc EUR | 138.26M | 5.76 | 5.56 | 6.05 | ||
European Growth Fund A DIST Eue | 6.47B | 5.54 | 4.70 | 5.19 | ||
European Growth Fund Y DIST EUR | 64.45M | 5.81 | 5.59 | 6.05 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.31 | 912.9 | -0.46% | |
L'Oreal | FR0000120321 | 4.15 | 453.50 | -0.72% | |
Relx | GB00B2B0DG97 | 4.06 | 3,455.00 | -0.20% | |
AstraZeneca | GB0009895292 | 3.87 | 12,166.0 | -0.05% | |
Allianz | DE0008404005 | 3.86 | 266.30 | +1.14% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review